



Published in final edited form as:

Nat Genet. ; 44(3): 307–311. doi:10.1038/ng.1087.

Meta-analysis identifies common variants associated with body mass index in East Asians

A full list of authors and affiliations appears at the end of the article.

Abstract

Multiple genetic loci associated with obesity or body mass index (BMI) have been identified through genome-wide association studies conducted predominantly in populations of European ancestry. We conducted a meta-analysis of associations between BMI and approximately 2.4 million SNPs in 27,715 East Asians, followed by *in silico* and *de novo* replication in 37,691 and 17,642 additional East Asians, respectively. We identified ten BMI-associated loci at the genome-wide significance level ($P < 5.0 \times 10^{-8}$), including seven previously identified loci (*FTO*, *SEC16B*, *MC4R*, *GIPR/QPCTL*, *ADCY3/RBJ*, *BDNF*, and *MAP2K5*) and three novel loci in or near the *CDKALI*, *PCSK1*, and *GP2* genes. Three additional loci nearly reached the genome-wide significance threshold, including two previously identified loci in the *GNPDA2* and *TFAP2B* genes and a new locus near *PAX6*, which all had $P < 5.0 \times 10^{-7}$. Findings from this study may shed light on new pathways involved in obesity and demonstrate the value of conducting genetic studies in non-European populations.

Since 2007, genome-wide association studies (GWAS) have contributed to a major leap forward in understanding the genetic basis of obesity^{1–11}. To date, 37 genetic loci associated with obesity or body mass index (BMI) have been identified through these GWAS. However, virtually all of these studies were conducted in populations of European ancestry and included limited data from Asian populations^{9, 11}. Asians, which account for over 60% of the world's population, have a greater percentage of body fat and higher metabolic

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Address for correspondence: Xiao Ou Shu, M.D., Ph.D., Professor of Medicine, Division of Epidemiology, Vanderbilt Epidemiology Center, 2525 West End Avenue, Suite 600, IMPH, Nashville, TN37203-1738, Tel: 615-936-0713, Fax: 615-936-8291, xiao-ou.shu@vanderbilt.edu.

*These authors contributed equally.

#These authors jointly directed this work.

Author Contributions

(in alphabetical order for each contribution)

T.A., Y.-S.C., Y.-T.G., D.-F.G., B.-G.H., J.H., F.B.H, N. Kamatami, N. Kato, L. L.-M., J.-H.L., W.L., Z.-N.M., Y.N., D.P.-K.N., L.Q., S.-M.S., X.-O.S., E.-S.T., F.T., T. Tanaka, F.J.T., T.-Y.W., J.-Y.W., Y.-B.X., J.-F.X., W.Z., and D.-L.Z. supervised the research. Y.-S.C., D.-F.G., J.H., Y.-L.H., N. Kato, J. Liang, Z.-N.M., Y.N., L.Q., M.S., X.-O.S., H.-D.S., E.-S.T., T. Tanaka, T.-Y.W., W.Z., and D.-L.Z. conceived and designed the experiments. J.H., Y.-L.H., M.K., J. Liang, M.S., J.-J.S., M.Y., and Y.Z. performed the experiments. L.C.C., C.-H.C., G.-K.C., R.D., M.-J.G., M.H., Y.-L.H., C.L., J. Long, Y.O., L.Q., M.-H.S., Y.T., F.K., A.-H.T., T. Tsunoda, and W.W. performed the statistical analyses. The GIANT Consortium, Q.C., L.-C.C., C.-H.C., R.J.D., R.D., M.-J.G., M.H., Y.-L.H., N.I., J. Long, T.M., Y.O., R.T.H.O., L.Q, X.S., M.H.S., and Y.T. analyzed the data. T.A., Q.C., Y.-T.G., C.A.H., B.E.H., N.I., N. Kato, Y.K., L.L.-M., J. Liang, J.-J.L., W.L., D.P.-K.N., L.Q., S.-M.S., M.S., X.-O.S., H.-D.S., E.-S.T., F.-J.T., T.-Y.W., J.-Y.W., Y.-B.X., K.Y., M.Y., and W.Z. contributed reagents/materials/analysis tools. R.J.D., Y.O., X.-O.S., E.-S.T., T. Tanaka, W.W., and W.Z. wrote the paper. All authors reviewed and approved the final version of the manuscript.

Competing Financial Interests: The authors declare that they have no competing financial interests.

disease risk than European-ancestry individuals with the same BMI¹². Therefore, studies conducted in Asian populations not only allow an evaluation of whether genetic markers of obesity identified in North American and European populations can be generalized to Asians, but also facilitate the dissection of the genetic architecture of obesity and the identification of genetic variants of particular importance to Asians.

We began with an initial genome-wide association meta-analysis using BMI as the primary outcome based on approximately 2.4 million genotyped or imputed SNPs generated from eight GWAS including 27,715 East Asians (stage I). This was followed by an *in silico* replication analysis conducted among 37,691 East Asians from an additional seven GWAS (stage II) and subsequently a *de novo* replication conducted among 17,642 East Asians from three studies (stage III). All of these studies were conducted in populations of East Asian ancestry; details of the study designs are presented in Supplementary Figure 1 and described in the Supplementary Note and Supplementary Tables 1 to 3.

The stage I meta-analysis was performed using the METAL program (<http://www.sph.umich.edu/csg/abecasis/Metal>), and study-specific genomic control adjustment was applied (see ONLINE METHODS). The Stage I analysis revealed that three well established loci (*FTO*, *SEC16B*, and *MC4R*) were associated with BMI at or near the genome-wide significance level ($P < 5 \times 10^{-8}$)¹³ (Table 1, Figure 1).

In stage II, we analyzed 798 SNPs with a P value $< 1.0 \times 10^{-4}$ in stage I and 50 additional SNPs that were previously reported to be associated with BMI in studies conducted in European-ancestry populations but that did not reach $P < 1.0 \times 10^{-4}$ in stage I. Seven additional GWAS conducted in East Asian populations participated in stage II and provided regression analysis results for the selected SNPs. These data, along with the stage I meta-analysis results, were combined again in meta-analyses using methods similar to stage I with adjustment for both study-specific genomic control inflation and estimated residual inflation for the stage I meta-analysis results, which was 1.056 (see ONLINE METHODS). Analysis of combined data from stages I and II revealed that the index SNPs in six previously reported loci (*FTO*, *SEC16B*, *MC4R*, *GIPR/QPCTL*, *ADCY3/RBJ*, and *BDNF*) were genome-wide significant ($P < 5.0 \times 10^{-8}$) and in three other previously reported loci (*GNPDA2*, *TFAP2B*, and *MAP2K5*) were near genome-wide significant ($P < 5.0 \times 10^{-7}$) in East Asians (Table 1, Supplementary Table 4). In addition, the index SNPs in nine other previously reported loci were associated with BMI in the East Asian data at the nominal significance level ($P < 0.05$) (Supplementary Table 4).

We compared two SNPs at each of the three loci *GIPR/QPCTL*, *ADCY3/RBJ*, and *MAP2K5* (Supplementary Table 5), one identified by our study and another by the GIANT consortium (published during the course of our study)⁸. The SNPs at *ADCY3/RBJ* and *MAP2K5* identified in our study are in linkage disequilibrium (LD) with the ones identified by the GIANT consortium. At *GIPR/QPCTL*, the SNP identified by our study, rs11671664, is not in LD in Asians ($r^2 = 0.026$) and is in weak LD in Europeans ($r^2 = 0.264$) with the SNP identified by the GIANT consortium, rs2287019. The latter was not in a statistically significant association with BMI in East Asians (see also Supplementary Table 4). Conditional analyses (see ONLINE METHODS) with the two SNPs in each locus included

in the same model for mutual adjustment showed that a statistically significant association with BMI remained only for the SNP identified by our study (Supplementary Table 5), suggesting that the SNP we identified may represent an independent association signal at the same locus in Asians.

The reported effect sizes for BMI-related SNPs in studies of European ancestry populations are usually greater than 3% of the standard deviation of BMI⁴. Given the sample sizes of our study (N=27,715 for stage I and N=65,406 for stages I and II combined), we had adequate statistical power (>0.8) to detect a SNP with such an effect size and with a MAF>0.2 in stage I or a MAF>0.08 in the combined stage I and II data at a significance level of $P<0.05$. The index SNPs in the 19 previously identified loci that were not replicated in our study at $P<0.05$ had either very small effect sizes or very low MAFs (two were not available, seven were monomorphic according to the HapMap Asian data) in East Asians (Supplementary Table 4).

We selected one representative SNP from each of seven loci for further replication, including the four loci at or near the *CDKALI*, *PCSK1*, *PAX6*, and *GP2* genes that have not previously been reported to be associated with BMI and the three loci at the *GIPR/QPCTL*, *ADCY3/RBJ*, and *MAP2K5* genes that were reported by the GIANT consortium (the selection of these SNPs was completed before the publication of the GIANT paper)⁸(Supplementary Table 4). Replication for these seven SNPs was conducted in stage III using *de novo* genotyping data from three study sites that included a total of 17,642 subjects (Supplementary Table 1 and 2). SNPs at other reported BMI loci that were genome-wide significant in stage I and II data were not included in the stage III *de novo* replication study for cost saving purposes. Stage III analyses found that the direction of the associations between BMI and the seven SNPs were consistent with stages I and II. The final results derived from a meta-analysis of data from all three stages combined, with adjustment for both study-specific genomic control inflation and estimated residual inflation for the stage I meta-analysis results, showed that six SNPs at or near *GIPR/QPCTL*, *ADCY3/RBJ*, *MAP2K5*, *CDKALI*, *PCSK1*, and *GP2* were associated with BMI at the genome-wide significance level ($P=1.02\times 10^{-8}$ to 5.93×10^{-14}) (Table 1) and SNP rs652722 near the *PAX6* gene nearly reached the genome-wide significance threshold ($P=7.65\times 10^{-8}$) (Supplementary Table 6). The explained variances of these SNPs are also presented in Table 1.

We also evaluated the association of BMI with these seven SNPs in data obtained from the GIANT consortium. Three of these SNPs (rs654581, rs4776970, and rs1167166) at the three loci that were recently reported by the GIANT consortium⁸ (*AGCY3/RBJ*, *MAP2K5*, and *GIPR/QPCTL*) and one newly identified SNP (rs261967) near the *PCSK1* gene exhibited a significant association with BMI at $P<0.007$ ($=0.05/7$, to account for seven tests for seven SNPs) (Supplementary Table 7). Although the effect sizes of these seven loci were smaller than those of the well established variants in the *FTO*, *MC4R*, and *SEC16B* loci (2.55–4.22 percentile of standard deviation of normal deviate versus 5.51–7.92, Table 1), their effect sizes were larger and the explained variances were bigger among East Asians than among Europeans (Supplementary Table 7, data obtained from the GIANT consortium), with the exception of SNP rs4776970 in the *MAP2K5* gene, which was independently identified by

both our study and the GIANT consortium. The explained variance of this SNP is 0.03% in Europeans (Supplementary Table 7) and 0.02% in Asians (Table 1).

As shown in Table 1, the *FTO* SNP had the biggest effect on BMI and accounted for the largest proportion of the variance (0.18%) in our study population, as compared with 0.34% estimated from the GIANT consortium⁸. Together, the 10 BMI loci that reached the genome-wide significance level explained 0.87% of the inter-individual variation in BMI. In order to provide a comparison with data from the GIANT consortium, we also estimated the inter-individual variation in BMI explained by all 22 loci that were associated with BMI at $P < 0.05$, including the above 10 SNPs with a genome-wide significant association (Supplementary Table 4). These 22 loci explained 1.18% of the inter-individual variation in BMI in our study population (see ONLINE METHODS). These explained variances are lower than those reported by the GIANT consortium (1.45% for overall and 0.34% for *FTO*)⁸. Even after excluding SNPs within these 22 loci associated with BMI at $P < 0.05$, the number of SNPs with small observed P values for an association with BMI still appeared to exceed the expected number (Figure 2), suggesting that additional BMI-related loci remain to be uncovered in these East Asian populations.

As shown in Supplementary Table 6, the associations with BMI for the SNPs in the four new loci at or near the *CDKALI*, *PCSK1*, *PAX6*, and *GP2* genes were consistent across studies. Stratified analyses by sex and population showed that associations for all four loci were similar between men and women (P for homogeneity test = 0.0837) and across Chinese, Japanese, Korean, and Malay populations (P for homogeneity test = 0.185). Meta-analyses performed after excluding 23,093 subjects with chronic disease (cancer or diabetes), found similar associations, although with less significant P values due to the decreased sample size. Meta-analyses of obesity as a dichotomous outcome (BMI ≥ 27.5)¹⁴ also showed similar associations with odds ratios per allele ranging from 1.05 to 1.10, although the statistical power for this analysis was lower (Supplementary Table 8). Of the studies participating in our analyses, one stage II study (SCORM) was based on children (aged 9 years). Analysis of data from the SCORM study showed that all the four loci had an association with BMI consistent with the meta-analysis, and SNP rs652722 near the *PAX6* gene was nominally significant ($P = 0.0335$) (Supplementary Table 6). Additional analysis excluding the SCORM study showed little change in the results.

The consistency of the findings across studies and populations suggests that population structure alone cannot account for the significant associations we identified. In addition, multiple SNPs in LD with each other showed similar associations in the combined stage I and II data at each locus (Figure 3, Supplementary Table 9). This plus the finding of similar associations in the *de novo* replication suggest that our results are unlikely to have been caused by genotyping or imputation errors.

The locus represented by SNP rs9356744 (6p22.3) contains the *CDKALI* gene, which has been reported to affect type 2 diabetes risk in a number of studies^{15–17}. A recent study reported an association between a *CDKALI* SNP, rs4712526, and BMI at age 8 years¹⁸. SNP rs4712526 was not included in our stage II replication set, but our stage I data for this SNP showed results consistent with the previous report (the minor allele *A* was associated

with lower BMI, $P=1.75\times 10^{-4}$, Supplementary Table 10). The SNP we identified, rs9356744, is in strong LD with rs4712526 ($r^2=0.87$) in Asians. To date, no study has reported an association between *CDKAL1* variants and adult BMI. Given the strong link between type 2 diabetes and obesity, we carried out additional analyses and reevaluated the association with BMI after excluding participants with type 2 diabetes. A similar association was observed, although the P value ($P=4.01\times 10^{-8}$) was less significant (Supplementary Table 6). These results indicate that the association of rs9356744 with BMI cannot be explained by the inclusion of subjects with diabetes. Additionally, two SNPs in the *CDKAL1* gene (rs9356744 and rs9368222, Supplementary Table 9) are cis-expression quantitative trait loci (eQTLs) for the nearby *E2F3* gene, a transcription factor and tumor suppressor¹⁹. Okada et al²⁰ identified another SNP (rs2206734) in the *CDKAL1* gene. While the data obtained from the GIANT consortium showed no significant association of our identified SNP rs9356744 with BMI ($P=0.186$, Supplementary Table 7), a nominally significant association ($P=0.0049$, Table 1 in Okada et al²⁰) between rs2206734 and BMI was observed in the GIANT consortium data. This discrepancy could be explained by differences in genetic architecture between East Asians and Europeans. SNPs rs9356744 and rs2206734 are in strong LD in Asians ($r^2=0.932$) and in weaker LD in Europeans ($r^2=0.396$). Taken together, the findings of our study and those of Okada et al, suggest that the functional SNP encoding risk for obesity is in LD with both rs9356744 and rs2206734 in East Asians but only with rs2206734 in populations of European ancestry. These differences in patterns of LD may facilitate further fine mapping to identify the functional variant by combining data across ethnic groups.

At the chromosome 5 locus (5q15), the top SNP, rs261967, along with 13 other SNPs that are in strong LD ($r^2=1.0$) with it, all reached the genome-wide significance threshold in the combined stage I and II data (Supplementary Table 9). The nearest gene to this locus is *PCSK1* (81.3kb away). A study using the candidate-gene approach reported two common non-synonymous coding variants (rs6234, rs6235) in the *PCSK1* gene that were associated with obesity²¹. However, these two SNPs showed no association with BMI in our study (Supplementary Table 10). None of the 14 SNPs identified at this locus by our study are in LD with the previously reported *PCSK1* SNPs ($r^2=0$) according to HapMap Asian data. Although SNP rs261967 was not statistically significant in the stage III replication, it showed an association with BMI ($P=0.00158$, Supplementary Table 7) in the data provided by the GIANT consortium⁸. Therefore, we believe that 5q15 represents a novel genetic locus for BMI and the association is unlikely to be a false positive finding.

The nearest genes flanking the chromosome 16 locus (16p12.3) are *GPR139* and *GP2*. Although only one SNP at this locus, rs12597579, reached the significance threshold of 1×10^{-4} for stage I screening and was therefore included in our stage II replication, multiple SNPs in this region showed an association with BMI that nearly met this significance threshold (Figure 3d). One of those SNPs, rs12598578 ($P=1.63\times 10^{-4}$, Supplementary Table 10), which is in LD ($r^2=0.968$ in Asians) with the identified SNP rs12597579, is highly conserved across species according to the TRANSFAC database²² and the common G allele creates a Ying-Yang transcription factor binding site (CONSITE <http://www.phylogood.org/consite>).

The top SNP at the chromosome 11 locus (11p13), rs652722, is approximately 66.0kb from the nearest gene, *PAX6*. However, SNP rs652722 exhibits no significant LD with SNPs in the *PAX6* gene or its 5' region according to HapMap and 1000 Genomes Project data. Nevertheless, rs652722 is in LD with several SNPs that are predicted to be eQTLs, according to the SCAN database²³, for a number of genes potentially important in the regulation of body weight. Among them is expression of the *MIF* gene based on HapMap lymphoblastoid cell lines. High plasma levels of MIF are related to higher BMI²⁴. Another gene associated with this eQTL is the *PFKP* gene, which, along with the *FTO* gene, has been associated with increased BMI, hip circumference, and weight². The association of BMI with rs652722 did not reach the conventional genome-wide significance level; thus, additional replication is needed.

Among the multiple hits at the *ADCY3/RBJ* locus (Supplementary Table 4), SNP rs11676272 ($P=5.88\times 10^{-10}$) is a predicted missense mutation and causes a Ser107Pro change in the *ADCY3* gene. This change is predicted to be potentially deleterious by Polyphen (<http://genetics.bwh.harvard.edu/pph/>). This locus is also associated with expression of the *POMC* gene, which regulates energy balance, thus, the susceptibility to obesity⁸. In addition, SNPs rs11676272 and rs6545814 at this locus ($r^2=0.98$ for LD between the two SNPs in Asians) are both eQTLs for the *ADCY3* gene²⁵.

In conclusion, our study identified 10 BMI-associated loci at the genome-wide significance level ($P<5.0\times 10^{-8}$), including seven loci previously identified by studies conducted among European-ancestry populations (*FTO*, *SEC16B*, *MC4R*, *GIPR/QPCTL*, *ADCY3/RBJ*, *BDNF*, and *MAP2K5*) and three novel loci in or near the *CDKALI*, *PCSK1*, and *GP2* genes. Three additional loci nearly reached the genome-wide significance threshold, including two previously identified loci in the *GNPDA2* and *TFAP2B* genes and a new locus near *PAX6*, which all had $P<5.0\times 10^{-7}$. Of the three previously reported loci at *GIPR/QPCTL*, *ADCY3/RBJ*, and *MAP2K5*, conditional analyses with both SNPs at the same locus included in the same models showed that only the SNPs identified by our study were associated with BMI in East Asian populations. The representative SNP (rs261967) near the newly identified *PCSK1* gene exhibited a significant association ($P=0.00158$) with BMI in a European population. As expected, the explained variances of the previously reported loci were generally lower in East Asians compared with those in Europeans, while the explained variances for the newly identified loci from this study were generally larger in East Asians than in Europeans. Although the specific mechanisms through which these loci affect BMI and obesity require further study, the identification of new loci may shed light on new pathways involved in obesity. In addition, fine mapping of multi-ethnic populations could lead to identification of causal links.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Wanqing Wen^{1,*}, Yoon Shin Cho^{2,*}, Wei Zheng^{1,*}, Rajkumar Dorajoo^{3,4,*}, Norihiro Kato^{5,*}, Lu Qi^{6,*}, Chien-Hsiun Chen^{7,8,*}, Ryan J. Delahanty¹, Yukinori Okada^{9,10}, Yasuharu Tabara¹¹, Dongfeng Gu¹², Dingliang Zhu^{13,14,15,16}, Christopher A. Haiman¹⁷, Zengnan Mo¹⁸, Yu-Tang Gao¹⁹, Seang Mei Saw²⁰, Min Jin Go², Fumihiko Takeuchi⁵, Li-Ching Chang⁷, Yoshihiro Kokubo²¹, Jun Liang²², Mei Hao²³, Loic Le Marchand²⁴, Yi Zhang^{13,14,15}, Yanling Hu²⁵, Tien Yin Wong^{26,27,28}, Jirong Long¹, Bok-Ghee Han², Michiaki Kubo²⁹, Ken Yamamoto³⁰, Mei-Hsin Su⁷, Tetsuro Miki³¹, Brian E. Henderson¹⁷, Huaidong Song³², Aihua Tan³³, Jiang He²³, Daniel P.-K. Ng²⁰, Qiuyin Cai¹, Tatsuhiko Tsunoda³⁴, Fuu-Jen Tsai⁸, Naoharu Iwai³⁵, Gary K. Chen¹⁷, Jiajun Shi¹, Jianfeng Xu³⁶, Xueling Sim³⁷, Yong-Bing Xiang¹⁹, Shiro Maeda³⁸, Rick T.H. Ong^{3,39}, Chun Li⁴⁰, Yusuke Nakamura⁴¹, Tin Aung^{26,27}, Naoyuki Kamatani⁹, Jian Jun Liu³, Wei Lu⁴², Mitsuhiro Yokota⁴³, Mark Seielstad^{3,44}, Cathy S.J. Fann⁷, The GIANT Consortium⁴⁵, Jer-Yuarn Wu^{7,8,#}, Jong-Young Lee^{2,#}, Frank B. Hu^{46,#}, Toshihiro Tanaka^{47,#}, E. Shyong Tai^{20,48,49,#}, and Xiao Ou Shu^{1,#}

Affiliations

¹Division of Epidemiology, Department of Medicine; Vanderbilt Epidemiology Center; and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

²Center for Genome Science, National Institute of Health, Osong Health Technology Administration Complex, Chungcheongbuk-do, Republic of Korea.

³Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore.

⁴Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, United Kingdom.

⁵Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

⁶Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.

⁷Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

⁸School of Chinese Medicine, China Medical University, Taichung, Taiwan.

⁹Laboratory for Statistical Analysis, Center for Genomic Medicine (CGM), RIKEN, Yokohama, Japan.

¹⁰Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

¹¹Department of Basic Medical Research and Education, Ehime University Graduate School of Medicine, Toon, Japan.

- ¹²Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- ¹³State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- ¹⁴Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- ¹⁵Sino-French Research Center for Life Science and Genomics, Shanghai, China.
- ¹⁶Shanghai Key Laboratory of Vascular Biology, Shanghai, China.
- ¹⁷Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
- ¹⁸Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
- ¹⁹Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China.
- ²⁰Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
- ²¹Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.
- ²²Department of Endocrinology, the Central Hospital of Xuzhou, Affiliated Hospital of Southeast University, Xuzhou, Jiangsu, China.
- ²³Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
- ²⁴Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, USA.
- ²⁵Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
- ²⁶Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
- ²⁷Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- ²⁸Center for Eye Research Australia, University of Melbourne, East Melbourne, Australia.
- ²⁹Laboratory for Genotyping Development, CGM, RIKEN, Yokohama, Japan.
- ³⁰Division of Genome Analysis, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
- ³¹Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan.

³²Ruijin Hospital, State Key Laboratory of Medical Genomics, Molecular Medical Center, Shanghai Institute of Endocrinology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

³³Center for Metabolic Disease and Diabetes, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.

³⁴Laboratory for Medical Informatics, CGM, RIKEN, Yokohama, Japan.

³⁵Department of Genomic Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

³⁶Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

³⁷Centre for Molecular Epidemiology, National University of Singapore, Singapore, Singapore.

³⁸Laboratory for Endocrinology and Metabolism, CGM, RIKEN, Yokohama, Japan.

³⁹NUS Graduate School for Integrative Science and Engineering, National University of Singapore, Singapore, Singapore.

⁴⁰Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

⁴¹Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

⁴²Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.

⁴³Department of Genome Science, Aichi-Gakuin University, School of Dentistry, Nagoya, Japan.

⁴⁴Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA.

⁴⁵Contributors to the GIANT consortium is provided in the supplementary material.

⁴⁶Departments of Epidemiology and Nutrition, Harvard University School of Public Health, Boston, Massachusetts, USA.

⁴⁷Laboratory for Cardiovascular Diseases, CGM, RIKEN, Yokohama, Japan.

⁴⁸Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

⁴⁹Duke-National University of Singapore Graduate Medical School, Singapore, Singapore.

ACKNOWLEDGEMENTS

The Shanghai Genome Wide Associations Studies (SGWAS) would like to thank the dedicated investigators and staff members from the research teams at Vanderbilt University, the Shanghai Cancer Institute, and the Shanghai Institute of Preventive Medicine, and most of all, the study participants for their contributions to the studies. Genotyping assays and statistical analyses for the SGWAS were supported primarily by NIH grants R01 CA064277, R37 CA070867, and R01 CA090899, R01 CA118229, R01 CA092585 and R01 CA122756, as well as

by Ingram professorship funds, Allen Foundation funds, and Vanderbilt CTSA grant 1 UL1 RR024975 from NCCR/NIH. Grant support for the participating studies include: the Shanghai Breast Cancer Study (R01 CA064277), the Shanghai Breast Cancer Survival Study (R01 CA118229), the Shanghai Endometrial Cancer Study (R01 CA092585). The KARE project was supported by grants from the Korea Centers for Disease Control and Prevention, Republic of Korea (4845-301, 4851-302, 4851-307). The Singapore Prospective Study Program (SP2) was funded through grants from the Biomedical Research Council of Singapore (BMRC 05/1/36/19/413 and 03/1/27/18/216) and the National Medical Research Council of Singapore (NMRC/1174/2008). E.S.T. also receives additional support from the National Medical Research Council through a clinician scientist award (NMRC/CSA/008/2009). The Singapore Malay Eye Study (SiMES) was funded by the National Medical Research Council (NMRC 0796/2003 and NMRC/STaR/0003/2008) and Biomedical Research Council (BMRC, 09/1/35/19/616). The CAGE Network Studies were supported by grants for the Core Research for Evolutional Science and Technology (CREST) from the Japan Science Technology Agency; the Program for Promotion of Fundamental Studies in Health Sciences, National Institute of Biomedical Innovation Organization (NIBIO); and the Grant of National Center for Global Health and Medicine (NCGM). Dr. Qi is supported by a grant from the National Institutes of Health (R01 HL071981), an American Heart Association Scientist Development Award, and the Boston Obesity Nutrition Research Center (DK46200). The Genetic Epidemiology Network of Salt Sensitivity (GenSalt) is supported by research grants (U01 HL072507, R01 HL087263, and R01 HL090682) from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. SINDI was funded by grants from Biomedical Research Council of Singapore (BMRC 09/1/35/19/616), Biomedical Research Council of Singapore (BMRC 08/1/35/19/550, Singapore), and National Medical Research Council of Singapore (NMRC/STaR/0003/2008). SCORM was funded by National Medical Research Council of Singapore (NMRC/0975/2005), Biomedical Research Council of Singapore (BMRC 06/1/21/19/466), and the Centre for Molecular Epidemiology, National University of Singapore. The SIH was supported by the Chinese National Key Program for Basic Research (Grant 973:2004CB518603) and Chinese National High Tech Program (Grant 863:2009AA022703). The MEC was supported by National Cancer Institute (NCI) grants CA063464, CA054281 and CA132839, as well as the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004726). Assistance with genotype cleaning for the MEC Japanese prostate cancer study was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Funding support for genotyping, which was performed at the Broad Institute of MIT and Harvard, was provided by the NIH GEI (U01 HG04424).

Reference List

1. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science*. 2007; 316:889–894. [PubMed: 17434869]
2. Scuteri A, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. *PLoS. Genet*. 2007; 3:e115. [PubMed: 17658951]
3. Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat. Genet*. 2008; 40:768–775. [PubMed: 18454148]
4. Thorleifsson G, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat. Genet*. 2009; 41:18–24. [PubMed: 19079260]
5. Willer CJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat. Genet*. 2009; 41:25–34. [PubMed: 19079261]
6. Meyre D, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat. Genet*. 2009; 41:157–159. [PubMed: 19151714]
7. Scherag A, et al. Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and German study groups. *PLoS. Genet*. 2010; 6:e1000916. [PubMed: 20421936]
8. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat. Genet*. 2010
9. Chambers JC, et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. *Nat. Genet*. 2008; 40:716–718. [PubMed: 18454146]
10. McCarthy MI. Genomics, type 2 diabetes, and obesity. *N. Engl. J. Med*. 2010; 363:2339–2350. [PubMed: 21142536]
11. Cho YS, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat. Genet*. 2009; 41:527–534. [PubMed: 19396169]
12. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes. Rev*. 2002; 3:141–146. [PubMed: 12164465]

13. de Bakker PI, et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. *Hum. Mol. Genet.* 2008; 17:R122–R128. [PubMed: 18852200]
14. WHO expert consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet.* 2004; 363:157–163. [PubMed: 14726171]
15. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat. Genet.* 2010; 42:579–589. [PubMed: 20581827]
16. Zeggini E, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science.* 2007; 316:1336–1341. [PubMed: 17463249]
17. Steinthorsdottir V, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nat. Genet.* 2007; 39:770–775. [PubMed: 17460697]
18. Winkler C, et al. BMI at age 8 years is influenced by the type 2 diabetes susceptibility genes HHEX-IDE and CDKAL1. *Diabetes.* 2010; 59:2063–2067. [PubMed: 20460429]
19. Veyrieras JB, et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. *PLoS. Genet.* 2008; 4:e1000214. [PubMed: 18846210]
20. Yukinori, Okada, et al. Common variants at CDKAL1 and KLF9 loci are associated with body mass index in East Asian populations (in submission).
21. Benzinou M, et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. *Nat. Genet.* 2008; 40:943–945. [PubMed: 18604207]
22. Wingender E, et al. TRANSFAC: an integrated system for gene expression regulation. *Nucleic Acids Res.* 2000; 28:316–319. [PubMed: 10592259]
23. Gamazon ER, et al. SCAN: SNP and copy number annotation. *Bioinformatics.* 2010; 26:259–262. [PubMed: 19933162]
24. Dandona P, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. *J. Clin. Endocrinol. Metab.* 2004; 89:5043–5047. [PubMed: 15472203]
25. Yang TP, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. *Bioinformatics.* 2010; 26:2474–2476. [PubMed: 20702402]
26. Zeggini E, Ioannidis JP. Meta-analysis in genome-wide association studies. *Pharmacogenomics.* 2009; 10:191–201. [PubMed: 19207020]
27. Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics.* 1954; 10:101–129.
28. Devlin B, Roeder K. Genomic control for association studies. *Biometrics.* 1999; 55:997–1004. [PubMed: 11315092]
29. Park JH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. *Nat. Genet.* 2010; 42:570–575. [PubMed: 20562874]
30. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res.* 2009; 37:W600–W605. [PubMed: 19417063]
31. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. *Nucleic Acids Res.* 2002; 30:3894–3900. [PubMed: 12202775]
32. Montgomery SB, et al. Transcriptome genetics using second generation sequencing in a Caucasian population. *Nature.* 2010; 464:773–777. [PubMed: 20220756]
33. Fujita PA, et al. The UCSC Genome Browser database: update 2011. *Nucleic Acids Res.* 2011; 39:D876–D882. [PubMed: 20959295]
34. Frazer KA, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature.* 2007; 449:851–861. [PubMed: 17943122]
35. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. *Nat. Rev. Genet.* 2006; 7:85–97. [PubMed: 16418744]




Figure 1. Manhattan plot showing the significance of associations between BMI and SNPs in the stage I data. The SNPs in previously reported genes showing significant associations with BMI are highlighted in red. The SNPs in newly identified loci are highlighted in blue.





Figure 2. Quantile-quantile plot for the association of BMI with SNPs in all stage I data (black) and after excluding SNPs in the 22 loci (red) with an association at $P < 0.05$ as shown in Supplementary Table 4.

**Figure 3.**

Regional plots of four novel loci identified in this study. SNPs are plotted by their position on the chromosome against their association ($-\log_{10} P$ value) with BMI using stage I (GWAS meta-analysis) data. The name and P value for the top SNP shown on the plots is based on all combined data with full genomic control adjustment (Table 1). The P value in stage I for the same SNP is denoted by a purple circle and indicated with an arrow. Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. The SNPs surrounding the top SNP are color-coded (see inset) to reflect their LD with the top SNP (using pair-wise r^2 values from HapMap CHB + JPT). Genes and positions of exons, as well as directions of transcription, are shown below the plots (using data from the UCSC Genome Browser, genome.ucsc.edu). Plots were generated using LocusZoom.

Table 1

Identified loci associated with BMI variation in East Asian populations

| Gene | Chr | SNP | Genotype ^a | EAF ^b | β (SE) ^c | P value by stages ^d | | | Explained Variance ^f |
|---------------------------------------|-----|------------|-----------------------|------------------|---------------------------|--------------------------------|----------|----------|---------------------------------|
| | | | | | | I | II | III | |
| Previously identified BMI loci | | | | | | | | | |
| <i>FTO</i> | 16 | rs17817449 | G/T | 0.17 | 7.92(1.06) | 6.13E-12 | 8.18E-14 | 4.60E-27 | 0.18% |
| <i>SEC16B</i> | 1 | rs574367 | T/G | 0.20 | 5.93(0.92) | 2.38E-11 | 1.28E-10 | 9.47E-20 | 0.11% |
| <i>MC4R</i> | 18 | rs6567160 | C/T | 0.21 | 5.51(0.93) | 6.92E-08 | 3.35E-09 | 2.76E-15 | 0.10% |
| <i>GIPR/QPCTL</i> | 19 | rs11671664 | G/A | 0.50 | 4.22(0.76) | 1.29E-05 | 2.57E-08 | 3.57E-03 | 0.09% |
| <i>ADCY3/RBJ</i> | 2 | rs6545814 | G/A | 0.45 | 3.26(0.76) | 1.20E-05 | 1.62E-05 | 1.35E-13 | 0.05% |
| <i>BDNF</i> | 11 | rs6265 | C/T | 0.44 | 4.97(0.83) | 1.18E-05 | 2.72E-09 | 3.56E-13 | 0.12% |
| <i>MAP2K5</i> | 15 | rs4776970 | A/T | 0.22 | 2.55(0.90) | 1.10E-06 | 4.63E-03 | 2.33E-09 | 0.02% |
| Newly identified BMI loci | | | | | | | | | |
| <i>CDKALI</i> | 6 | rs9356744 | T/C | 0.58 | 3.39(0.76) | 3.21E-05 | 7.67E-06 | 3.02E-03 | 0.06% |
| <i>PCKSI</i> | 5 | rs261967 | C/A | 0.41 | 3.77(0.77) | 1.22E-05 | 9.36E-07 | 8.46E-01 | 0.07% |
| <i>GP2</i> | 16 | rs12597579 | C/T | 0.80 | 4.09(0.96) | 7.13E-05 | 2.07E-05 | 1.45E-01 | 0.05% |

^a Shown as effect allele/other allele.

^b Effect allele frequency in Asians, estimated from stages I and II studies.

^c Per allele effect of SNPs (in percentage) on BMI, obtained from stage II data only.

^d Derived from meta-analysis. The p values for the combined data were adjusted for both study-specific inflation factors and the estimated inflation factor for the stage I meta-analysis statistic.

^e Combined all available data from three stages.

^f The effect sizes obtained from stage II data were used to estimate the explained variance.